Larimar Therapeutics, Inc.
LRMR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LRMR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LRMR
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing nomlabofusp, a potential treatment for Friedreich's ataxia, with a Phase 3 trial underway and a cash position of $92.7 million as of June 30, 2026.
Key risk: Clinical trial delays
BioSniper Score
Based on 6 of 6 signals
Market Cap
$416.6M
Cash Runway
10.5 moLead Asset
nomlabofusp (Phase 1)Next Catalyst
Phase3_Topline · Dec 1, 2029Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 3 clinical trials · 1 catalyst for Larimar Therapeutics, Inc..
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing nomlabofusp, a potential treatment for Friedreich's ataxia, with a Phase 3 trial underway and a cash position of $92.7 million as of June 30, 2026.
- Larimar Therapeutics is developing nomlabofusp, a product candidate for Friedreich's ataxia, with a Phase 3 trial initiated in mid-2026 [sec_mda · as of 2026-05-14].
- As of June 30, 2026, the company reported cash and equivalents of $92.7 million, a net loss of $32.8 million for the six-month period, and shareholders' equity of $78.1 million [sec].
- The company has an accumulated deficit of $497.2 million as of June 30, 2026, and expects to incur significant operating losses for the foreseeable future [sec_mda · as of 2026-08-04].
- Larimar plans to submit final modules of its biologics license application, including the CMC module, in the second half of 2026, targeting a U.S. launch in the first half of 2027 if approved [sec_mda · as of 2026-05-14].
- The company's Phase 2 open-label extension study (NCT06447025) is recruiting, while a Phase 1 study (NCT06681766) was terminated [catalyst].
What works
- Larimar has a clear regulatory pathway with FDA and EMA feedback on its Phase 3 protocol, supporting a potential U.S. launch in early 2027 [sec_mda · as of 2026-05-14].
- The company has sufficient cash to fund operations into the fourth quarter of 2026, based on prior guidance, providing a runway through key milestones [sec_mda · as of 2025-08-14].
What to weigh
- Larimar has a significant accumulated deficit of $497.2 million as of June 30, 2026, and has not generated any product revenue, with no expectation of near-term sales [sec_mda · as of 2026-08-04].
- The company faces substantial uncertainty in clinical trial timelines, costs, and regulatory approvals, which could delay or prevent commercialization [sec_mda · as of 2026-08-04].
- Larimar's cash position of $92.7 million as of June 30, 2026, may not be sufficient to complete all required clinical development without additional financing [sec_mda · as of 2026-08-04].
From the filings
Quoted directly from source documents.
Larimar has an accumulated deficit of $497.2 million as of June 30, 2026.
“As of June 30, 2026, we had an accumulated deficit of $497.2 million.”
SEC MD&A · August 4, 2026
Larimar plans to submit final BLA modules in the second half of 2026.
“plan to submit the final modules, including the CMC module, in the second half of 2026.”
SEC MD&A · May 14, 2026
Larimar expects to incur significant expenses and operating losses for the foreseeable future.
“We expect to incur significant expenses and operating losses for the foreseeable future as we expect to continue to incur expenses in connection with our ongoing activities”
SEC MD&A · August 4, 2026
Larimar's Phase 2 open-label extension study is recruiting.
“Phase 2 Start: An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, Pharmacodynamics, Pharmacoki - NCT: NCT06447025. Status: Recruiting.”
Catalysts · January 25, 2024
Catalyst timeline
- 2029-12-01 · Phase3_Topline — Topline data from the Phase 3 randomized, double-blind, placebo-controlled study of nomlabofusp for Friedreich's ataxia.
Risks & what to watch (3)›
Key risks
- Clinical trial delays — Unexpected delays in clinical trials could negatively impact operations and cash runway [sec_mda · as of 2026-08-04].
- Regulatory approval uncertainty — The FDA or other authorities may not approve nomlabofusp, delaying or preventing commercialization [sec_mda · as of 2026-08-04].
- Financing risk — Current cash may not be sufficient to complete development without additional capital, leading to dilution [sec_mda · as of 2026-08-04].
What to watch
- Submission of final BLA modules, including CMC, in the second half of 2026 [sec_mda · as of 2026-05-14].
- Initiation and enrollment progress of the Phase 3 confirmatory study, with first patient dosing planned for mid-2026 [sec_mda · as of 2026-05-14].
- Cash runway updates, as prior guidance indicated funding into Q4 2026 [sec_mda · as of 2025-08-14].
- Potential FDA decision on nomlabofusp, targeting U.S. launch in first half of 2027 if approved [sec_mda · as of 2026-05-14].
Sources: Catalysts · SEC MD&A · Generated August 24, 2026 · How we verify sources →
Run Larimar Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Larimar Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
10.5 months
D/E 0.30
Lead: Phase 1
1 candidate
1 upcoming, next in ~1189d
1 buy · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
160
Total value held
$371.0M
| Holder | Shares | Value |
|---|---|---|
| deerfield management company, l.p. | 35,606,974 | $160.2M |
| vanguard capital management llc | 5,732,698 | $25.8M |
| blackrock, inc. | 3,752,200 | $16.9M |
| millennium management llc | 3,625,278 | $16.3M |
| driehaus capital management llc | 2,934,399 | $13.2M |
| woodline partners lp | 2,801,700 | $12.6M |
| dafna capital management llc | 2,029,164 | $9.1M |
| goldman sachs group inc | 1,651,585 | $7.4M |
| deep track capital, lp | 1,500,000 | $6.8M |
| rtw investments, lp | 1,500,000 | $6.8M |
Showing top 10 of 160 institutional holders of Larimar Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 12.4%
- Days to cover
- 6.2
- Shares short
- 8,309,598
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LRMR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Larimar Therapeutics, Inc.?
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing nomlabofusp, a potential treatment for Friedreich's ataxia, with a Phase 3 trial underway and a cash position of $92.7 million as of June 30, 2026.
What is Larimar Therapeutics, Inc.'s lead drug candidate?
Larimar Therapeutics, Inc.'s most advanced tracked candidate is nomlabofusp (Phase 1) for Friedreich Ataxia.
What is Larimar Therapeutics, Inc.'s next catalyst?
Larimar Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy a" — expected December 1, 2029.
Who is the CEO of Larimar Therapeutics, Inc.?
Dr. Carole S. Ben-Maimon M.D. is the chief executive officer of Larimar Therapeutics, Inc. (LRMR).
Where is Larimar Therapeutics, Inc. headquartered?
Larimar Therapeutics, Inc. (LRMR) is headquartered in Bala Cynwyd, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.